Abstracts tagged "Patient reported outcomes"

Abstract Number: PP13 • ACR Convergence 2024
Bridging the Gap from Pediatric to Adult Rheumatology Care
Natasha Trehan, University of Ottawa, Take a Pain Check Foundation, Markham, ON, Canada
Background/Purpose: When I was 13, life took an unexpected turn with a diagnosis of Juvenile Idiopathic Arthritis (JIA). Overnight, my world transformed into a cycle…
Abstract Number: 0548 • ACR Convergence 2024
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
David Kiefer¹, Juergen Braun², Uta Kiltz³, Niklas Kolle¹, Lucia Schneider¹, Ioana Andreica⁴, Bjoern Buehring⁵, Philipp Sewerin⁶, Imke Redeker⁷, Styliani Tsiami⁸, Susanne Herbold⁹ and Xenofon Baraliakos⁸, ¹Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁵Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, ⁶Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Ruhr Universität Bochum, Bochum, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Herne, Germany
Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
Abstract Number: 0682 • ACR Convergence 2024
Results from Outcomes Selection and Development of a Patient-reported Outcome Measure for a Combined Response Index for Limited Cutaneous SSc: The CRISTAL Project
Alain Lescoat¹, Yen Chen², Susan Murphy³, Nadia Vann², Neda Kortam², Rosemary Gedert², Sue Farrington⁴, Yannick Allanore⁵, David Cella⁶, Lorinda Chung⁷, Philip Clements⁸, Christopher Denton⁹, Francesco Del Galdo¹⁰, Oliver Distler¹¹, Monique Hinchcliff¹², Michael Hughes¹³, Laura Hummers¹⁴, John Pauling¹⁵, Janet Pope¹⁶, Virginia Steen¹⁷, John Varga², Peter Merkel¹⁸, Maya H. Buch¹⁹ and Dinesh Khanna², and all CRISTAL collaborators, ¹CHU Rennes - University Rennes 1, Rennes, France, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Plymouth, MI, ⁴Scleroderma & Raynaud UK, London, United Kingdom, ⁵Université Paris Cité, Paris, France, ⁶Northwestern University, Chicago, IL, ⁷Stanford University, Woodside, CA, ⁸United States, Los Angeles, CA, ⁹University College London, Northwood, United Kingdom, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹²Yale School of Medicine, Westport, CT, ¹³Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ¹⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ¹⁵North Bristol NHS Trust, Bristol, United Kingdom, ¹⁶University of Western Ontario, London, ON, Canada, ¹⁷Georgetown University School of Medicine, Washington, DC, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures available to assess symptoms…
Abstract Number: 1237 • ACR Convergence 2024
The Art of Choosing Together: Unveiling the Patient’s Perspective in Rheumatology
ADRIANA VANEGAS¹, Guillermo Quiceno², Luis Lira³, Gina Ochoa⁴, Álvaro Arbeláez-Cortés⁵, Mauricio Restrepo-Escobar⁶ and Virginia Pascual Ramos⁷, ¹HOSPITAL SAN VICENTE FUNDACION - UNIVERSIDAD DE ANTIOQUIA - Asociación Colombiana de Reumatología (ASOREUMA), MEDELLIN, Colombia, ²University of Tennessee Graduate School of Medicine, Dallas, TX, ³Sociedad Chilena de Reumatología, Santiago, Chile, ⁴Fundación LICAR, Barranquilla, Colombia, ⁵Clínica IMBANACO, Cali, Colombia, ⁶Universidad de Antioquia, Retiro, Colombia, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico
Background/Purpose: Scientific evidence supports that shared decision-making (SDM) can improve adherence to treatment, patient satisfaction, quality of life, clinical outcomes, and healthcare costs. However, challenges…
Abstract Number: 1324 • ACR Convergence 2024
Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations
Shirish Dubey¹, Abhinav Peddasomayajula², Damodar Makkuni³, Anupama Nandagudi⁴, Win Win Maw⁵ and Gouri M Koduri⁶, ¹Oxford University Hospitals NHS FT, Oxford, United Kingdom, ²Mid and South Essex NHS Foundation Trust, Southend, England, United Kingdom, ³James Paget University Hospital NSH FT, Great Yarmouth, United Kingdom, ⁴MSEFT, Basildon, United Kingdom, ⁵Mid and South Essex NHS Foundation Trust, Chelmsford, England, United Kingdom, ⁶Southend Univeristy Hospitals NHS Trust, Essex, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is one of the complications of rheumatoid arthritis (RA) and has significant impact on morbidity and mortality. RA significantly reduces…
Abstract Number: 1555 • ACR Convergence 2024
Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
Vibeke Strand¹, Kenneth Kalunian², Ian Bruce³, Caroline Seo⁴, Kai Wai Lee⁵, Jacob Knagenhjelm⁶ and Catharina Lindholm⁶, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of California San Diego, La Jolla, CA, ³Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁴BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Fatigue is highly prevalent and severely affects health-related quality of life (HRQoL) in patients with SLE.1,2 We previously demonstrated that, compared with placebo, a…
Abstract Number: 2153 • ACR Convergence 2024
Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Lourdes Perez Chada¹, Ruogu Li², vivi feathers², Kumiko Schnock², Helen Early², Grace Carter², Neda Shahriari², Arianna Zhang², Jing Cui³, Michael Weinblatt⁴, Nancy Shadick², Alice Gottlieb⁵ and Joseph Merola⁶, ¹Harvard Medical School, Wayland, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Patients with psoriasis often present with musculoskeletal (MSK) symptoms, yet validated instruments to measure MSK symptoms in this population are limited. The IDEOM MSK-Q…
Abstract Number: 2265 • ACR Convergence 2024
Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁷ and Klaus Krüger⁹, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Rheumatology, Tübingen, Germany, ⁴Hannover Medical School, Department for Rheumatology and Immunology, Herne, Germany, ⁵Knappschaftsklinikum Saar GmbH, Püttlingen, Germany, ⁶StatConsult GmbH, Statistics, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Immunology, Wiesbaden, Germany, ⁸AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, ⁹Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany
Background/Purpose: Patient’s Global Assessment of disease activity (PtGA) was found to be the most relevant limiting factor for achieving Boolean 1.0 remission in patients with…
Abstract Number: 0171 • ACR Convergence 2024
Associations Between Discrimination Experiences and Patient-Reported Outcomes Among Asian Individuals with Systemic Lupus Erythematosus (SLE)
Patti Katz¹, JoonSuk Park², Kamil Barbour³, Kurt Greenlund³, Maria Dall'Era⁴ and Jinoos Yazdany², ¹UCSF, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³CDC, Alpharetta, GA, ⁴UCSF, Corte Madera, CA
Background/Purpose: Discrimination experiences have been linked to poor outcomes among Black individuals with SLE.1 Among Asian adults in the general US population, discrimination has been…
Abstract Number: 0560 • ACR Convergence 2024
Association Between a Self-Report Screening Tool for Sarcopenia (SARC-F) and Disease Activity, Muscle Strength and Muscle Power Measures, Patient-Reported Outcomes and Body Composition in Patients with Spondyloarthritides
Iuliia Kononenko¹, Marius Bedei², Bjoern Buehring³, Xenofon Baraliakos⁴ and Uta Kiltz⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Bochum, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Herne, Germany, ³Bergisches Rheuma-Zentrum, Wuppertal, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany
Background/Purpose: The SARC-F is a self-report screening tool for sarcopenia (Sar) used to identify individuals at risk for poor functional outcomes [1]. The aim of this study was…
Abstract Number: 0702 • ACR Convergence 2024
AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study
Andrew Sternlicht¹ and Meredith Todd², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia
Background/Purpose: Improved treatments for Raynaud's phenomenon in Systemic Sclerosis (SSc) are needed. A novel oral calcium channel blocker (cilnidipine), with N-type channel antagonism is being…
Abstract Number: 1238 • ACR Convergence 2024
Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², seoidin McKittrick³, Robert Harrington⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland, ⁴St. James's Hospital, Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: One of the most significant unmet needs in the management of those with Polymyalgia Rheumatica (PMR) is the lack of a disease stratification tool…
Abstract Number: 1331 • ACR Convergence 2024
Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?
Sofia Pedro¹, Kristin Wipfler², Urbano Sbarigia³, Federico Zazzetti⁴, Anna Sheahan⁵, Patti Katz⁶ and Kaleb Michaud⁷, ¹Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Janssen, Chapel Hill, NC, ⁶UCSF, San Rafael, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Refractory rheumatoid arthritis (reRA) is characterized by an inadequate response to multiple DMARDs. Many factors including environment, comorbidities, sociodemographics, and the treatment itself influence poor…
Abstract Number: 1563 • ACR Convergence 2024
Prevalence, Risk Factors and Associations for Osteoporosis in Postmenopausal Women with Scleroderma
Gayane Matusov¹, Jon Giles² and Francesco Boin³, ¹Scripps Clinic, San Diego, CA, ²Cedars Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Case-control studies have shown that systemic sclerosis (SSc) patients exhibit higher prevalence of osteoporosis (OP) compared to subjects in the general population. The pathophysiology…
Abstract Number: 2154 • ACR Convergence 2024
“I Have Taken Five Different Kinds of Tablets and Injections, and I Still Have Foot Pain”: An International Outcome Measures in Rheumatology (OMERACT) Qualitative Study Exploring Patient Perspectives of Foot and Ankle Disorders
Lara Chapman¹, Caroline Flurey², Anthony C. Redmond¹, Pam Richards³, Eiman Soliman⁴, Abdelhfeez Moshrif⁵, Lucy Malone⁶, Christopher Joyce⁷, Marian Hannan⁸, Philip S. Helliwell⁹, Catherine Hofstetter¹⁰, Hylton Menz¹¹, Beverley Shea¹² and Heidi Siddle¹, ¹University of Leeds, Leeds, United Kingdom, ²University of the West of England, Bristol, Bristol, United Kingdom, ³OMERACT, Bristol, United Kingdom, ⁴Alexandria Faculty of Medicine, Alexandria, Egypt, ⁵Al-azhar university, Assiut, Egypt, ⁶Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom, ⁷Homerton Healthcare NHS Foundation Trust, London, United Kingdom, ⁸Marcus Institute for Aging Research, Hebrew SeniorLife, Milton, MA, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ¹⁰OMERACT, Toronto, Canada, ¹¹La Trobe University, Fairfield, Victoria, Australia, ¹²Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: The foot and ankle are frequently affected in rheumatic and musculoskeletal diseases (RMDs), yet there is a lack of high-quality evidence to determine the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].